Disease · MONDO_0006968

shoulder impingement syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. shoulder impingement syndrome. Diseases, record MONDO_0006968. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006968

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: shoulder impingement syndrome; Open Targets
Open Targets ID: MONDO_0006968; Open Targets
Other names: Impingement syndrome of shoulder region, Impingement syndrome of shoulder region (disorder), Subacromial impingement (disorder), shoulder impingement syndrome (disorder) [ambiguous]; Open Targets
Disease Ontology: DOID:14276; Disease Ontology
MeSH: D019534; MeSH
Highest stage of its drugs: Phase 2, for 5 of its 7 drugs, from ClinicalTrials.gov; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LIDOCAINE	CHEMBL79	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
TETRACAINE	CHEMBL698	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
KETOROLAC TROMETHAMINE	CHEMBL1201124	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
METHYLPREDNISOLONE ACETATE	CHEMBL1364144	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TRIAMCINOLONE ACETONIDE	CHEMBL1504	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
KETOROLAC	CHEMBL469	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
TRIAMCINOLONE	CHEMBL1451	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets13

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
PTGS1	Cyclooxygenase	2	Cyclooxygenase inhibitor	Phase 2	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	2	Cyclooxygenase inhibitor	Phase 2	https://conductscience.org/library/genes/5743	Drugs and targets
SCN10A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6328	Drugs and targets
SCN4A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6329	Drugs and targets
SCN5A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6331	Drugs and targets

1 to 10 of 13

See all 13 targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03913702	Subacromial Methylprednisolone Versus Ketorolac for Shoulder Impingement	Phase 2	1	2025-01-03	Subacromial Impingement, Subacromial Impingement Syndrome	KETOROLAC TROMETHAMINE, METHYLPREDNISOLONE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT01544283	Pain Patch Versus Injections in the Treatment of Pain Associated With Shoulder Impingement Syndrome	Phase 2	60		Shoulder Pain	LIDOCAINE, TETRACAINE, TRIAMCINOLONE ACETONIDE	Its record names the disease	ClinicalTrials.gov
NCT01055444	Study Evaluating Heated Lidocaine/Tetracaine Topical Patch in Treatment of Patients With Shoulder Impingement Syndrome	Phase 2	20		Shoulder Impingement Syndrome	LIDOCAINE, TETRACAINE	Its record names the disease	ClinicalTrials.gov
NCT01449448	Subacromial Injection With Corticosteroid Versus Nonsteroidal Anti-inflammatory Drugs (NSAID) in Shoulder Impingement Syndrome	Not applicable	0		Subacromial Impingement Syndrome, Subacromial Bursitis	KETOROLAC, TRIAMCINOLONE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
23177167	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006968

GET https://conductscience.org/api/diseases/v1/MONDO_0006968/drugs

API reference For AI assistants